SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

STRO

Sutro Biopharma, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Traders should monitor mid-2026 for initial STRO-004 clinical data, which could serve as a major value catalyst. The improved financial efficiency and extended cash runway reduce near-term dilution risk and support continued development of Sutro’s high-potential dual-payload ADC platform.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.57
T+0 close · Mar 23, 2026 · via day close
Latest settled
+25.71%
T+60 · $29.63
Vs SPY
+11.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $23.57entry
  2. T+1 · 8mo ago −0.30%α −0.86% · $23.50
  3. T+5 · 8mo ago +5.69%α +6.11% · $24.91
  4. T+20 · 7mo ago +50.74%α +41.84% · $35.53
  5. T+60 · 5mo ago +25.71%α +11.39% · $29.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sutro Biopharma reported its 2025 financial results, highlighted by a 65% year-over-year increase in revenue to $102.5 million, primarily from its Astellas and Ipsen collaborations, while significantly reducing R&D and G&A expenses. The company also announced clinical progress across its ADC pipeline, including dosing in a Phase 1 trial for STRO-004 and advancement of its dual-payload programs, supported by a $110 million capital raise extending its cash runway into Q2 2028.

Key Financial Metrics

Revenue
$102.5M
+65.3% YoY
EPS
$-22.49

Key Facts

  • Revenue increased 65% YoY to $102.5 million in 2025, up from $62.0 million in 2024, driven by collaboration income from Astellas and Ipsen.
  • Total operating expenses dropped from $300.5 million in 2024 to $260.9 million in 2025, with R&D spending down 34% despite ongoing clinical development.
  • Cash, cash equivalents, and marketable securities totaled $141.4 million as of December 31, 2025, and a $110 million equity raise extended the cash runway into at least Q2 2028.
  • STRO-004 Phase 1 trial completed dosing in three cohorts, with initial clinical data expected mid-2026.
  • STRO-227, a dual-payload ADC targeting PTK7, remains on track for IND submission in 2026.
  • Astellas began patient dosing in a dual-payload iADC trial, triggering a $10 million milestone expected in Q2 2026, and a second program triggered a $7.5 million payment in late 2025.

Financial Impact

Revenue increased by $40.5 million YoY while reducing operating expenses by $39.6 million, improving financial efficiency. The $110 million capital raise significantly extends operational runway.

revenueoperating expensescash runwaynet loss

Risk Factors

  • As a clinical-stage company, Sutro remains dependent on clinical trial outcomes, which are inherently uncertain.
  • Future revenue is heavily tied to collaboration milestones, which may be delayed or not achieved.
  • The company has a stockholders' equity deficit of $132.5 million, indicating ongoing reliance on external financing.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260829

Track record

8 reports on STRO

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +5.09% at T+1 after the Nov 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $9.82 to $9.32 Now $9.32 +5.09% ▲ +5.09% +3.18% vs SPY
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $10.61 to $10.17 Now $9.32 −12.16% ▼ −4.15% −3.78% vs SPY
  3. Aug 12, 202613w ago 8-K Bullish 7/10 No price data
  4. Aug 12, 202613w ago Press Release Mixed 6/10 Entry $21.30 to $21.31 Now $9.32 −56.24% ▲ +0.05% −0.65% vs SPY
  5. Apr 22, 202629w ago DEFA14A Neutral 3/10 Entry $34.83 to $33.33 Now $9.32 −73.24% ▼ −4.31% −5.09% vs SPY
  6. Apr 19, 202630w ago Press Release Bullish 7/10 Entry $34.58 to $34.35 Now $9.32 −73.05% ▼ −0.67% −0.01% vs SPY
  7. Mar 23, 202634w ago S-3 Bearish 6/10 Entry $23.57 to $23.50 Now $9.32 +60.46% ▲ +0.30% +0.86% vs SPY
  8. Mar 23, 202634w ago Press Release Bullish 7/10 Viewing Entry $23.57 to $23.50 Now $9.32 −60.46% ▼ −0.30% −0.86% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026